ArticleEClinicalMedicine2021

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.

Gerald Falchook et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.